2017
Cumulative childhood maltreatment and its dose-response relation with adult symptomatology: Findings in a sample of adult survivors of sexual abuse
Steine IM, Winje D, Krystal JH, Bjorvatn B, Milde AM, Grønli J, Nordhus IH, Pallesen S. Cumulative childhood maltreatment and its dose-response relation with adult symptomatology: Findings in a sample of adult survivors of sexual abuse. Child Abuse & Neglect 2017, 65: 99-111. PMID: 28131947, DOI: 10.1016/j.chiabu.2017.01.008.Peer-Reviewed Original ResearchConceptsCumulative childhood maltreatmentChildhood maltreatmentPosttraumatic stressSexual abuseSocial supportChildhood adversityAdult survivorsRule-governed wayHierarchical regression analysisChildhood maltreatment experiencesSelf-harm behaviorsDose-response relationCumulative childhood adversityAdult symptomatologyDisorder symptomsSelf-reported symptomsPsychological distressRelational problemsSymptom complexityMaltreatment experiencesWork functioningEmotional painRelated distressMaltreatment scoresAdversity
2016
Implication of NOTCH1 gene in susceptibility to anxiety and depression among sexual abuse victims
Steine IM, Zayats T, Stansberg C, Pallesen S, Mrdalj J, Håvik B, Soulé J, Haavik J, Milde AM, Skrede S, Murison R, Krystal J, Grønli J. Implication of NOTCH1 gene in susceptibility to anxiety and depression among sexual abuse victims. Translational Psychiatry 2016, 6: e977-e977. PMID: 27959334, PMCID: PMC5290341, DOI: 10.1038/tp.2016.248.Peer-Reviewed Original ResearchMeSH KeywordsAllelesAnimalsAnxiety DisordersBrainDepressive DisorderDisease Models, AnimalFemaleGene ExpressionGenetic Predisposition to DiseaseHumansLife Change EventsMaleNeurodevelopmental DisordersPolymorphism, Single NucleotideRats, WistarReceptor, Notch1Sex OffensesTranslational Research, BiomedicalConceptsSingle nucleotide polymorphismsDifferent early-life conditionsGene expressionEarly-life conditionsBrain gene expressionGenetic association studiesCandidate genesAssociation studiesNeural developmentDifferential expressionTag single nucleotide polymorphismsBrain of rodentsGenesHuman samplesFalse discovery rateNotch1 geneSymptoms of anxietyExpressionSignificance analysisDiscovery ratePotential importanceEarly life stressMeans of correspondencePotential relevancePlk5Genome-wide significant loci for addiction and anxiety
Hodgson K, Almasy L, Knowles EE, Kent JW, Curran JE, Dyer TD, Göring HH, Olvera RL, Fox PT, Pearlson GD, Krystal JH, Duggirala R, Blangero J, Glahn DC. Genome-wide significant loci for addiction and anxiety. European Psychiatry 2016, 36: 47-54. PMID: 27318301, PMCID: PMC5483998, DOI: 10.1016/j.eurpsy.2016.03.004.Peer-Reviewed Original ResearchConceptsLinkage scanLinkage signalGenome-wide significant lociSignificant quantitative trait lociGenome-wide linkage scanBivariate linkage scanSignificant positive genetic correlationQuantitative trait lociGene of interestBivariate linkage analysisPositive genetic correlationAddiction phenotypeGenomic lociGenetic architectureTrait lociPleiotropic signalsSignificant lociChromosomal regionsAddiction geneticsGenetic underpinningsLinkage analysisPrevious GWASGenetic correlationsNovel regionRole of genetics
2010
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal JH, Mathew SJ, D’Souza D, Garakani A, Gunduz-Bruce H, Charney DS. Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. CNS Drugs 2010, 24: 669-693. PMID: 20658799, DOI: 10.2165/11533230-000000000-00000.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPreliminary clinical trialsPositive allosteric modulatorsPsychiatric disordersClinical trialsAnimal modelsAllosteric modulatorsGroup II mGluR agonistGroup IMetabotropic glutamate receptor agonistAnxiety disordersPotential psychiatric applicationsGlutamate receptor agonistsMetabotropic glutamate receptorsTreatment of schizophreniaRole of glutamateForm of depressionMGluR agonistAntidepressant propertiesMGluR5 agonistReceptor agonistGlutamate receptorsMood disordersArea of schizophreniaPromising agentAgonists
2009
Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia
Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discovery Today 2009, 14: 690-697. PMID: 19460458, PMCID: PMC2898127, DOI: 10.1016/j.drudis.2009.05.002.Peer-Reviewed Original ResearchConceptsPsychiatric disordersSymptomatic reliefMood disordersAnxiety disordersNeuroplasticity deficitsCurrent pharmacotherapyUnderlying abnormalityCurrent treatmentPsychiatric treatmentNeuroplasticityDisordersPharmacotherapyTreatmentExciting new findingsSchizophreniaReliefAbnormalitiesNeurodevelopmentNew findingsPrevention
2008
Riluzole in the Treatment of Mood and Anxiety Disorders
Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G. Riluzole in the Treatment of Mood and Anxiety Disorders. CNS Drugs 2008, 22: 761-786. PMID: 18698875, DOI: 10.2165/00023210-200822090-00004.Peer-Reviewed Original ResearchConceptsTreatment of moodAnxiety disordersMultiple molecular actionsOpen-label trialPlacebo-controlled trialAmino acid neurotransmissionCommon adverse effectsLiver function testsAmyotrophic lateral sclerosisVoltage-gated sodium channelsBorderline personality disorderSelf-injurious behaviorStandard therapyIll patientsBipolar depressionFunction testsObsessive-compulsive disorderCase reportGlutamatergic neurotransmissionGlutamate levelsExtracellular glutamateClinical consequencesLateral sclerosisAstrocytic uptakeRiluzoleA Meta-Analysis of D-Cycloserine and the Facilitation of Fear Extinction and Exposure Therapy
Norberg MM, Krystal JH, Tolin DF. A Meta-Analysis of D-Cycloserine and the Facilitation of Fear Extinction and Exposure Therapy. Biological Psychiatry 2008, 63: 1118-1126. PMID: 18313643, DOI: 10.1016/j.biopsych.2008.01.012.Peer-Reviewed Original ResearchConceptsExposure therapyFear extinctionD-cycloserineNMDA receptor functionPartial N-methyl-d-aspartate (NMDA) receptor agonistEffects of DCSExposure-based therapyExposure-based treatmentsFear memory consolidationReceptor functionN-methyl-D-aspartate receptor agonistMemory consolidationDCS doseTranslational researchExposure procedureTherapy literatureEnglish-language journal articlesReceptor agonistQuantitative reviewTrial designMeta-AnalysisTherapyStudy authorsTypes of subjectsEffective agent
2005
Untangling depression and anxiety: clinical challenges.
Keller MB, Krystal JH, Hen R, Neumeister A, Simon NM. Untangling depression and anxiety: clinical challenges. The Journal Of Clinical Psychiatry 2005, 66: 1477-84. PMID: 16420087, DOI: 10.4088/jcp.v66n1119.Peer-Reviewed Original Research
2001
CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS
Krystal J, D'Souza D, Sanacora G, Goddard A, Charney D. CURRENT PERSPECTIVES ON THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA, DEPRESSION, AND ANXIETY DISORDERS. Medical Clinics Of North America 2001, 85: 559-577. PMID: 11349473, DOI: 10.1016/s0025-7125(05)70329-1.Peer-Reviewed Original Research
1997
Positron Emission Tomography Measurement of Cerebral Metabolic Correlates of Yohimbine Administration in Combat-Related Posttraumatic Stress Disorder
Bremner JD, Innis RB, Ng CK, Staib LH, Salomon RM, Bronen RA, Duncan J, Southwick SM, Krystal JH, Rich D, Zubal G, Dey H, Soufer R, Charney DS. Positron Emission Tomography Measurement of Cerebral Metabolic Correlates of Yohimbine Administration in Combat-Related Posttraumatic Stress Disorder. JAMA Psychiatry 1997, 54: 246-254. PMID: 9075465, DOI: 10.1001/archpsyc.1997.01830150070011.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderAdministration of yohimbineNorepinephrine releaseHealthy subjectsHealthy age-matched control subjectsAge-matched control subjectsStress disorderDouble-blind fashionPositron emission tomography (PET) measurementsBrain metabolic responsesCerebral metabolic correlatesBrain norepinephrine releaseSymptoms of anxietyPositron emission tomographyBrain metabolismControl subjectsYohimbine administrationPreclinical studiesMetabolic correlatesCaudate nucleusPatientsYohimbineVietnam combat veteransEmission tomographyOrbitofrontal cortex
1995
Effects of the benzodiazepine antagonist flumazenil in PTSD
Randall P, Bremner J, Krystal J, Nagy L, Heninger G, Nicolaou A, Charney D. Effects of the benzodiazepine antagonist flumazenil in PTSD. Biological Psychiatry 1995, 38: 319-324. PMID: 7495926, DOI: 10.1016/0006-3223(94)00306-n.Peer-Reviewed Original ResearchConceptsVisual analogue rating scaleAdministration of flumazenilAnxiety symptomsCrossover study designBenzodiazepine antagonist flumazenilGABAA receptor complexBenzodiazepine/GABAA receptor complexPanic disorder patientsAnalogue rating scalesFlumazenil administrationPTSD Symptom ScaleIntravenous infusionAntagonist flumazenilGABAA antagonistHealthy controlsClinical studiesDisorder patientsSymptom ScaleFlumazenilPanic disorderPanic attacksVietnam combat veteransStudy designRating ScalePTSD symptomsNoradrenergic response to acute ethanol administration in heathly subjects: comparison with intravenous yohimbine
McDougle C, Price L, Heninger G, Krystal J, Charney D. Noradrenergic response to acute ethanol administration in heathly subjects: comparison with intravenous yohimbine. Psychopharmacology 1995, 118: 127-135. PMID: 7617798, DOI: 10.1007/bf02245830.Peer-Reviewed Original ResearchConceptsAcute ethanol administrationEthanol administrationPlasma MHPGIntravenous yohimbineBlood pressureNE turnoverSystolic blood pressureAlpha2-adrenergic receptorsPlacebo-controlled designBlood pressure measurementsEthanol-induced increaseHealthy human subjectsClear additive effectSubjective measuresNE metabolismNoradrenergic responsesNorepinephrine metaboliteCombined administrationMHPG responsePlasma levelsPharmacokinetic effectsOral administrationIntravenous administrationAnxiogenic effectsEthanol intoxication
1991
Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder
Woods S, Charney D, Silver J, Krystal J, Heninger G. Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. Psychiatry Research 1991, 36: 115-127. PMID: 1850142, DOI: 10.1016/0165-1781(91)90124-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnalysis of VarianceAnxiety DisordersDouble-Blind MethodFemaleFlumazenilHumansMaleMiddle AgedPanicPlacebosReceptors, GABA-AConceptsAntagonist flumazenilAnxiolytic effectsBenzodiazepine receptor antagonist flumazenilReceptor antagonist flumazenilDose of flumazenilVisual analog scaleBenzodiazepine receptor functionBZR inverse agonistsSignificant anxiolytic effectSeparate test daysPlacebo capsulesBlood pressureAnalog scaleCardiovascular responsesDisorder patientsHeart rateFlumazenilCrossover designPanic patientsPanic disorderPlasma cortisolBaseline levelsPanic attacksPlaceboReceptor function
1990
Noradrenergic function in panic disorder.
Charney DS, Woods SW, Nagy LM, Southwick SM, Krystal JH, Heninger GR. Noradrenergic function in panic disorder. The Journal Of Clinical Psychiatry 1990, 51 Suppl A: 5-11. PMID: 2258377.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnxiety DisordersCatsHumansLocus CoeruleusMacacaModels, NeurologicalNorepinephrinePanicSympathetic Nervous SystemConceptsLocus ceruleusNoradrenergic functionPanic disorderBrain noradrenergic functionNoradrenergic neuronal activityPanic disorder patientsNoradrenergic neuronsPreclinical evidenceNatural courseNoradrenergic nucleusDevelopment of anxietyAnxiogenic effectsClinical investigationDisorder patientsNeuronal activityUncontrollable stressNeuron firingNonhuman primatesNeurodevelopmental perspectiveLaboratory animalsSystem regulationFear responsesDisordersAnxietyElectrical activationSerotonin Function and Human Anxiety Disordersa
CHARNEY D, WOODS S, KRYSTAL J, HENINGER G. Serotonin Function and Human Anxiety Disordersa. Annals Of The New York Academy Of Sciences 1990, 600: 558-572. PMID: 2252335, DOI: 10.1111/j.1749-6632.1990.tb16910.x.Peer-Reviewed Original ResearchSpecificity of Serotonin Reuptake Inhibitors in the Treatment of Obsessive-Compulsive Disorder: Comparison of Fluvoxamine and Desipramine
Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS. Specificity of Serotonin Reuptake Inhibitors in the Treatment of Obsessive-Compulsive Disorder: Comparison of Fluvoxamine and Desipramine. JAMA Psychiatry 1990, 47: 577-585. PMID: 2112374, DOI: 10.1001/archpsyc.1990.01810180077011.Peer-Reviewed Original ResearchConceptsSerotonin reuptake inhibitorsObsessive-compulsive disorderReuptake inhibitorsComparison of fluvoxamineSerotonin receptor functionDouble-blind fashionGlobal response rateWeeks of treatmentBaseline depressive symptomsYale-Brown Obsessive Compulsive ScaleMechanism of actionObsessive Compulsive ScaleReuptake inhibitionDopaminergic functionPrincipal diagnosisDepressive symptomsResponse rateFluvoxamineDesipramineReceptor functionObsessive-compulsive symptomsDesipramine hydrochlorideCompulsive ScaleSymptomsFluvoxamine maleateMarijuana (cannabis) use is anecdotally said to precipitate anxiety symptoms in patients with panic disorder. Is there any research evidence to support this? Also, can marijuana use precipitate or expose paranoia in patients with an underlying bipolar disorder?
SEIBYL J, KRYSTAL J, CHARNEY D. Marijuana (cannabis) use is anecdotally said to precipitate anxiety symptoms in patients with panic disorder. Is there any research evidence to support this? Also, can marijuana use precipitate or expose paranoia in patients with an underlying bipolar disorder? Journal Of Clinical Psychopharmacology 1990, 10: 78. PMID: 2307743, DOI: 10.1097/00004714-199002000-00033.Peer-Reviewed Original ResearchSerotonin-Specific Drugs for Anxiety and Depressive Disorders
Charney DS, Krystal JH, Delgado PL, Heninger GR. Serotonin-Specific Drugs for Anxiety and Depressive Disorders. Annual Review Of Medicine 1990, 41: 437-446. PMID: 2139556, DOI: 10.1146/annurev.me.41.020190.002253.Peer-Reviewed Original ResearchMeSH KeywordsAnxiety DisordersDepressive DisorderHumansNeurotransmitter Uptake InhibitorsReceptors, SerotoninSerotoninSerotonin Antagonists
1989
Clinical and Medication Outcome After Short-term Alprazolam and Behavorial Group Treatment in Panic Disorder: 2.5-Year Naturalistic Follow-up Study
Nagy LM, Krystal JH, Woods SW, Charney DS. Clinical and Medication Outcome After Short-term Alprazolam and Behavorial Group Treatment in Panic Disorder: 2.5-Year Naturalistic Follow-up Study. JAMA Psychiatry 1989, 46: 993-999. PMID: 2818144, DOI: 10.1001/archpsyc.1989.01810110035005.Peer-Reviewed Original ResearchConceptsFU periodAlprazolam treatmentMajor depressionPanic disorderPanic attacksPanic attack frequencyBehavioral group treatment programGreater symptom severityAntipanic effectsNonpharmacologic therapiesMedication outcomesNaturalistic followGroup treatment programAlprazolam dosesSame doseLow doseLifetime diagnosisAttack frequencySymptom severityTreatment programBehavioral therapyPatientsAdmissionAlprazolamTreatment gains